The global digital therapeutics market size was valued at USD 2.88 Billion in 2019 and is expected to reach USD 13.80 Billion by 2027 with a CAGR of 20.5% during the forecast period. The increasing adoption of mobile and tablet devices, the expansion of healthcare apps, the growing need to track healthcare expenses, and the rising incidence of chronic diseases are all driving the worldwide digital therapeutics market. Furthermore, the digital therapeutics industry's producers could profit handsomely from significant growth possibilities in undeveloped areas.
.jpg)
Digital therapeutics is a subset of digital health that offers patients evidence-based therapy options that are supported by high-quality software. The difference between digital health and digital therapeutics is based on the clinical outcomes of the patients.
The widespread availability of smartphones has resulted in a significant shift in how individuals use their devices to access healthcare, making it a perfect platform for delivering cutting-edge digital therapy. During the forecast period, the market size for digital therapeutics is predicted to grow due to the increasing penetration of digital devices such as smartphones and tablets.
The expansion of the digital therapeutics market has been fueled by rising healthcare costs. Due to escalating drug and service prices, healthcare costs have risen to unsustainable levels in recent years. As a result, large corporations and the government-run healthcare system have begun to employ new treatments.
In order to scale up to a large number of patients and enhance healthcare results, digital therapies are increasingly being used. Digital treatment has proven its worth in the management of diabetes and other chronic diseases. As a result, the market for digital therapeutics is likely to grow as the prevalence of chronic disease rises.
The expansion of the digital therapeutics market is hampered by a lack of awareness about digital therapeutics in developing countries, as well as concerns about patient data protection.
On the basis of application, the digital therapeutics market is segmented into diabetes, obesity, cardiovascular disease, central nervous system disease, respiratory disease, smoking cessation, gastrointestinal disorder, and others. The diabetes segment was the major revenue contributor in 2019, and is anticipated to continue this trend during the forecast period, owing to high prevalence of diabetes. In addition, demand for cost-effective healthcare options and highest comparative prevalence rates for diabetes are observed in North America, the Middle East, and North Africa, which further boosts the demand for digital therapeutics among diabetic patients in these regions. However, the obesity segment is projected to exhibit the highest growth during the forecast period.
This is attributed to increase in number of overweight populations, which increases the number of chronic diseases, owing to obesity. In addition, better accessibility of digital therapeutics software application help patients to maintain their proper diet as well as track health data and daily physical activities. Moreover, the software application provides regular online assistance from certified doctors, which is expected to help in reducing prevalence of obesity in the future. Furthermore, several companies have launched a variety of digital therapeutics products. For instance, in 2017, Oxil launched an app to tackle increasing cases of obesity among youth. Moreover, Azumio provides fitness buddy mobile app that offers largest exercise database, which helps reduce obesity. The analysis done by Noom Inc. demonstrated that 78% of users lost weight with its mobile health coaching solutions.
Depending on product, the digital therapeutics market is categorized into software and devices. The software segment is projected to exhibit the highest growth during the forecast period. This is attributed to rise in demand for reducing healthcare costs across the world. This gives immense opportunities to developers to use existing software and develop new and advanced features to make them more effective and affordable. Thus, is anticipated to help in increasing the digital therapeutics market size in the future.
Region wise, the digital therapeutics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2019, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to increase in geriatric population, rise in incidences of chronic diseases, surge in demand for wireless & portable systems, and availability of sophisticated reimbursement structure that aims in reducing expenditure.
|
Report Metric |
Details |
|
Report Name |
Digital Therapeutics Market |
|
Market size value in 2019 |
USD 2.88 Billion |
|
Revenue forecast in 2027 |
USD 13.80 Billion |
|
CAGR |
20.5% |
|
By Product Type |
Software, Device |
|
By Application |
Diabetes, Obesity, Cardiovascular disease, Central nervous system disease, Respiratory disease, Smoking cessation, Gastrointestinal disorder |
|
By Sales Channel |
B2B, B2C |
Ans: The global digital therapeutics market size is expected to reach USD 13.80 Billion by 2027 with a CAGR of 20.5%.
Ans: Software segment is projected as one of the most lucrative segments.
Ans: Some of the major companies are 2MORROW, Inc., Akili Interactive Labs, Inc., Click Therapeutics, Inc., Fitbit, Inc. (Twine Health, Inc.), Happify, Inc., Kaia Health, Livongo Health, Inc., Medtronic Plc., Omada Health, Inc., Pear Therapeutics, Inc., Proteus Digital Health, Inc., Resmed, Inc. (Propeller Health), Voluntis, Inc., Welldoc, Inc.
Ans: Asia-Pacific region would exhibit the highest CAGR of 22.2% during 2020-2027.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key Market Segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning, 2019
3.4.Porter’s five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in adoption of smartphones and tablets, coupled with healthcare apps
3.5.1.2.Growth in need to control healthcare costs
3.5.1.3.Rise in incidences of chronic diseases
3.5.2.Restraints
3.5.2.1.Lack of awareness regarding digital therapeutics in developing countries
3.5.2.2.Patient data privacy concerns
3.5.3.Opportunity
3.5.3.1.Emerging markets offer significant growth opportunities
3.6.Impact analysis of COVID-19 on the digital therapeutics market
3.7.Impact of government regulations on global digital therapeutics market
3.7.1.U.S. FDA’s premarket clearance and approval requirements
3.7.2.European Union premarket clearance and approval requirements
3.7.3.Japan premarket clearance and approval requirements
3.8.Strategy adopted by top 10 start-ups
3.8.1.Meru Health, Inc.
3.8.2.Bold Health Limited
3.8.3.BehaVR, LLC
3.8.4.Naluri Hidup Sdn Bhd
3.8.5.Big Health
3.8.6.Hinge Health, Inc.
3.8.7.Glooko, Inc.
3.8.8.Holmusk Pte. Ltd.
3.8.9.Wellthy Therapeutics Pvt Ltd.
3.8.10.Virta Health Corp.
3.9.Key digital technologies for digital therapeutics
3.9.1.Mobile health (mHealth)
3.9.2.Personalized healthcare
3.9.3.Digital Cognitive Behavior Therapy (CBT)
3.9.4.Wearable devices and sensors
3.10.Necessary human resources required for digital therapeutics development
3.11.Usage of patient data acquired from digital therapeutics
3.11.1.Types of personal information that are collected by DTx companies
CHAPTER 4:DIGITAL THERAPEUTICS MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Diabetes
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Obesity
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Cardiovascular diseases
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Central nervous system (CNS) diseases
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.6.Gastrointestinal disorder
4.6.1.Key market trends and growth opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
4.7.Respiratory diseases
4.7.1.Key market trends and growth opportunities
4.7.2.Market size and forecast
4.7.3.Market analysis, by country
4.8.Smoking cessation
4.8.1.Key market trends and growth opportunities
4.8.2.Market size and forecast
4.8.3.Market analysis, by country
4.9.Others
4.9.1.Key market trends and growth opportunities
4.9.2.Market size and forecast
4.9.3.Market analysis, by country
CHAPTER 5:DIGITAL THERAPEUTICS MARKET, BY PRODUCT
5.1.Overview
5.1.1.Market size and forecast
5.2.Software
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Devices
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
CHAPTER 6:DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Business-to-business (B2B)
6.2.1.Market size and forecast, by type
6.2.1.1.Employer
6.2.1.1.1.Market size and forecast
6.2.1.2.Healthcare Providers
6.2.1.2.1.Market size and forecast
6.2.1.3.Others
6.2.1.3.1.Market size and forecast
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Business-to-consumers
6.3.1.Market size and forecast, by type
6.3.1.1.Patients
6.3.1.1.1.Market size and forecast
6.3.1.2.Caregivers
6.3.1.2.1.Market size and forecast
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
CHAPTER 7:DIGITAL THERAPEUTICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America digital therapeutics market, by country
7.2.2.1.U.S. digital therapeutics market, by application
7.2.2.2.U.S digital therapeutics market, by product type
7.2.2.3.U.S. digital therapeutics market, by sales channel
7.2.2.4.Canada digital therapeutics market, by application
7.2.2.5.Canada digital therapeutics market, by product type
7.2.2.6.Canada digital therapeutics market, by sales channel
7.2.2.7.Mexico digital therapeutics market, by application
7.2.2.8.Mexico digital therapeutics market, by product type
7.2.2.9.Mexico digital therapeutics market, by sales channel
7.2.3.North America digital therapeutics market, by application
7.2.4.North America digital therapeutics market, by product type
7.2.5.North America digital therapeutics market, by sales channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe digital therapeutics market, by country
7.3.2.1.UK digital therapeutics market, by application
7.3.2.2.UK digital therapeutics market, by product type
7.3.2.3.UK digital therapeutics market, by sales channel
7.3.2.4.Germany digital therapeutics market, by application
7.3.2.5.Germany digital therapeutics market, by product type
7.3.2.6.Germany digital therapeutics market, by sales channel
7.3.2.7.France digital therapeutics market, by application
7.3.2.8.France digital therapeutics market, by product type
7.3.2.9.France digital therapeutics market, by sales channel
7.3.2.10.Italy digital therapeutics market, by application
7.3.2.11.Italy digital therapeutics market, by product type
7.3.2.12.Italy digital therapeutics market, by sales channel
7.3.2.13.Spain digital therapeutics market, by application
7.3.2.14.Spain digital therapeutics market, by product type
7.3.2.15.Spain digital therapeutics market, by sales channel
7.3.2.16.Rest of Europe digital therapeutics market, by application
7.3.2.17.Rest of Europe digital therapeutics market, by product type
7.3.2.18.Rest of Europe digital therapeutics market, by sales channel
7.3.3.Europe digital therapeutics market, by application
7.3.4.Europe digital therapeutics market, by product type
7.3.5.Europe digital therapeutics market, by sales channel
7.4.Asia-pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific digital therapeutics market, by country
7.4.2.1.Japan digital therapeutics market, by application
7.4.2.2.Japan digital therapeutics market, by product type
7.4.2.3.Japan digital therapeutics market, by sales channel
7.4.2.4.China digital therapeutics market, by application
7.4.2.5.China digital therapeutics market, by product type
7.4.2.6.China digital therapeutics market, by sales channel
7.4.2.7.Australia digital therapeutics market, by application
7.4.2.8.Australia digital therapeutics market, by product type
7.4.2.9.Australia digital therapeutics market, by sales channel
7.4.2.10.India digital therapeutics market, by application
7.4.2.11.India digital therapeutics market, by product type
7.4.2.12.India digital therapeutics market, by sales channel
7.4.2.13.South Korea digital therapeutics market, by application
7.4.2.14.South Korea digital therapeutics market, by product type
7.4.2.15.South Korea digital therapeutics market, by sales channel
7.4.2.16.Rest of Asia-Pacific digital therapeutics market, by application
7.4.2.17.Rest of Asia-Pacific digital therapeutics market, by product type
7.4.2.18.Rest of Asia-Pacific digital therapeutics market, by sales channel
7.4.3.Asia-Pacific digital therapeutics market, by application
7.4.4.Asia-Pacific digital therapeutics market, by product type
7.4.5.Asia-Pacific digital therapeutics market, by sales channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA digital therapeutics market, by country
7.5.2.1.Brazil digital therapeutics market, by application
7.5.2.2.Brazil digital therapeutics market, by product type
7.5.2.3.Brazil digital therapeutics market, by sales channel
7.5.2.4.Turkey digital therapeutics market, by application
7.5.2.5.Turkey digital therapeutics market, by product type
7.5.2.6.Turkey digital therapeutics market, by sales channel
7.5.2.7.Saudi Arabia digital therapeutics market, by application
7.5.2.8.Saudi Arabia digital therapeutics market, by product type
7.5.2.9.Saudi Arabia digital therapeutics market, by sales channel
7.5.2.10.South Africa digital therapeutics market, by application
7.5.2.11.South Africa digital therapeutics market, by product type
7.5.2.12.South Africa digital therapeutics market, by sales channel
7.5.2.13.Rest of LAMEA digital therapeutics market, by application
7.5.2.14.Rest of LAMEA digital therapeutics market, by product type
7.5.2.15.Rest of LAMEA digital therapeutics market, by sales channel
7.5.3.LAMEA digital therapeutics market, by application
7.5.4.LAMEA digital therapeutics market, by product type
7.5.5.LAMEA digital therapeutics market, by sales channel
CHAPTER 8:COMPANY PROFILES
8.1.2MORROW, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Key strategic moves and developments
8.2.AKILI INTERACTIVE LABS, INC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio
8.2.4.Key strategic moves and developments
8.3.CLICK THERAPEUTICS, INC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Key strategic moves and developments
8.4.FITBIT, INC. (TWINE HEALTH, INC.)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance
8.4.5.Key strategic moves and developments
8.5.HAPPIFY, INC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Product portfolio
8.5.4.Key strategic moves and developments
8.6.KAIA HEALTH
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Product portfolio
8.6.4.Key strategic moves and developments
8.7.LIVONGO HEALTH, INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Product portfolio
8.7.4.Key strategic moves and developments
8.8.MEDTRONIC PLC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.OMADA HEALTH, INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Key strategic moves and developments
8.10.PEAR THERAPEUTICS, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Key strategic moves and developments
8.11.PROTEUS DIGITAL HEALTH, INC.
8.11.1.Company overview
8.11.2.Company snapshot
8.11.3.Operating business segments
8.11.4.Product portfolio
8.11.5.Key strategic moves and developments
8.12.RESMED, INC. (PROPELLER HEALTH)
8.12.1.Company overview
8.12.2.Company snapshot
8.12.3.Operating business segments
8.12.4.Product portfolio
8.12.5.Business performance
8.12.6.Key strategic moves and developments
8.13.VOLUNTIS, INC.
8.13.1.Company overview
8.13.2.Company snapshot
8.13.3.Operating business segments
8.13.4.Product portfolio
8.13.5.Business performance
8.13.6.Key strategic moves and developments
8.14.WELLDOC, INC.
8.14.1.Company overview
8.14.2.Company snapshot
8.14.3.Operating business segments
8.14.4.Product portfolio
8.14.5.Key strategic moves and developments
$6168
$10663
$6929
Add to Cart
Add to Cart
Add to Cart
Add to Cart